melatonin and Sleep Apnea Syndromes studies

Sleep Apnea Syndromes: Disorders characterized by multiple cessations of respirations during sleep that induce partial arousals and interfere with the maintenance of sleep. Sleep apnea syndromes are divided into central (see SLEEP APNEA, CENTRAL), obstructive (see SLEEP APNEA, OBSTRUCTIVE), and mixed central-obstructive types.

Research Excerpts

Excerpt	Relevance	Reference
"Melatonin has been advocated in treatment of sleep disorders, and its beneficial effect has been confirmed in insomnia."	6.75	Melatonin and sleep-related problems in children with intractable epilepsy. ( Abd-Elhamid, IA; Asaad, T; Elkhayat, HA; Elwakkad, AS; Hassanein, SM; Tomoum, HY, 2010)
"We hypothesised that melatonin may represent a safe somniferous drug for cardiac patients, and assessed the effects of administering 5 mg of melatonin daily before bedtime for 30 days in patients with coronary artery disease (CAD) regarding changes in the nocturnal breathing pattern."	5.16	Melatonin - a somniferous option which does not aggravate sleep-disordered breathing in cardiac risk patients: a Holter ECG based study. ( Kasprzak, JD; Krzemińska-Pakuła, M; Kurpesa, M; Rechciński, T; Trzos, E; Uznańska-Loch, B; Wierzbowska-Drabik, K, 2012)
" We aimed to investigate the proteins related to oxidative stress, inflammation and apoptosis in liver tissue subjected to IH as a simulation of sleep apnea in conjunction with the administration of either melatonin (MEL, 200 μL/kg) or N-acetylcysteine (NAC, 10 mg/kg)."	3.81	Antioxidants inhibit the inflammatory and apoptotic processes in an intermittent hypoxia model of sleep apnea. ( Andrade, CF; da Rosa, DP; e Silva, MB; Fiori, CZ; Forgiarini, LF; Marroni, NP; Martinez, D, 2015)
" Switching to morning dosing or to an alternative drug may help."	2.82	[Sleep disorders in patients with a neurocognitive disorder]. ( Carrier, J; Dang-Vu, TT; Moderie, C, 2022)
"Melatonin has been advocated in treatment of sleep disorders, and its beneficial effect has been confirmed in insomnia."	2.75	Melatonin and sleep-related problems in children with intractable epilepsy. ( Abd-Elhamid, IA; Asaad, T; Elkhayat, HA; Elwakkad, AS; Hassanein, SM; Tomoum, HY, 2010)
"While some sleep disorders are more challenging to treat, most can be easily managed with adequate interventions."	2.61	Sleep Disorders. ( K Pavlova, M; Latreille, V, 2019)
" The recognition of the periodicity of biological processes makes the optimal dosing of certain drugs feasible."	2.48	[Physiological and pathophysiological role of the circadian clock system]. ( Halmos, T; Suba, I, 2012)
"Fibromyalgia has gender, age and probably hormonal associations."	2.43	Menopause related sleep disorders. ( Eichling, PS; Sahni, J, 2005)
"Patients with dementias, such as Alzheimer's disease (AD), often have nocturnally disrupted sleep."	2.42	Sleep disorders in Alzheimer's disease and other dementias. ( Bliwise, DL, 2004)
"Non-REM parasomnias are not uncommon conditions in the general population."	1.51	NREM parasomnias: a treatment approach based upon a retrospective case series of 512 patients. ( d'Ancona, G; Dongol, EM; Drakatos, P; Gildeh, N; Higgins, S; Kent, BD; Leschziner, G; Lyons, E; Macavei, R; Marples, L; Muza, R; Nesbitt, A; Rosenzweig, I; Steier, J; Williams, AJ, 2019)
"The present results suggest that sleep fragmentation and any resultant cognitive deficits are likely not confounded by corresponding deficits in circadian rhythms."	1.46	Young children with Down syndrome show normal development of circadian rhythms, but poor sleep efficiency: a cross-sectional study across the first 60 months of life. ( Anand, P; Clark, C; Demara, BI; Edgin, JO; Fernandez, F; Nyhuis, CC; Ruby, NF; Spanò, G, 2017)
"Melatonin was successfully used as an alternative treatment."	1.35	REM sleep behaviour disorder treated with melatonin in a patient with Alzheimer's disease. ( Anderson, KN; Graham, AJ; Jamieson, S; Shneerson, JM, 2008)
"Effective treatments now exist for many sleep disorders, such as OSA and RLS, and a major breakthrough in the treatment of narcolepsy seems imminent."	1.32	Sleep disorders. ( Fisch, BJ; Olejniczak, PW, 2003)
"1."	1.30	Melatonin secretion and excretion in patients with obstructive sleep apnea syndrome. ( Röjdmark, S; Svanborg, E; Wetterberg, L; Wikner, J, 1997)
"Melatonin has a strong circadian rhythm with high values during the night-time and low values in the afternoon."	1.30	Afternoon serum-melatonin in sleep disordered breathing. ( Micic, S; Strøm, J; Ulfberg, J, 1998)

Research

Studies (20)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Epworth Sleepiness Score (ESS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (20.00)	18.2507
2000's	5 (25.00)	29.6817
2010's	9 (45.00)	24.3611
2020's	2 (10.00)	2.80

Authors	Studies
Moderie, C	1
Carrier, J	1
Dang-Vu, TT	1
Kennert, BA	1
Harshorne, TS	1
Kanouse, S	1
Johnson, C	1
Fernandez, F	1
Nyhuis, CC	1
Anand, P	1
Demara, BI	1
Ruby, NF	1
Spanò, G	1
Clark, C	1
Edgin, JO	1
Drakatos, P	1
Marples, L	1
Muza, R	1
Higgins, S	1
Gildeh, N	1
Macavei, R	1
Dongol, EM	1
Nesbitt, A	1
Rosenzweig, I	1
Lyons, E	1
d'Ancona, G	1
Steier, J	1
Williams, AJ	1
Kent, BD	1
Leschziner, G	1
K Pavlova, M	1
Latreille, V	1
da Rosa, DP	1
Forgiarini, LF	1
e Silva, MB	1
Fiori, CZ	1
Andrade, CF	1
Martinez, D	1
Marroni, NP	1
Mahlberg, R	1
Elkhayat, HA	1
Hassanein, SM	1
Tomoum, HY	1
Abd-Elhamid, IA	1
Asaad, T	1
Elwakkad, AS	1
Rechciński, T	1
Uznańska-Loch, B	1
Trzos, E	1
Wierzbowska-Drabik, K	1
Krzemińska-Pakuła, M	1
Kasprzak, JD	1
Kurpesa, M	1
Szymański, FM	1
Halmos, T	1
Suba, I	1
Olejniczak, PW	1
Fisch, BJ	1
Bliwise, DL	1
Eichling, PS	1
Sahni, J	1
Anderson, KN	1
Jamieson, S	1
Graham, AJ	1
Shneerson, JM	1
Entzian, P	1
Linnemann, K	1
Schlaak, M	1
Zabel, P	1
Wikner, J	1
Svanborg, E	1
Wetterberg, L	1
Röjdmark, S	1
Ulfberg, J	1
Micic, S	1
Strøm, J	1
Manber, R	1
Armitage, R	1
Dauvilliers, Y	1
Touchon, J	1

Trial	Enrollment	Study Type	Start Date	Status
Study of the Influence of an Osteopathic Treatment Protocol on the Improvement of Sleep: a Double-blind Randomized Controlled Trial[NCT05899972]	50 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Effect of Melatonin Supplementation on Sleep and Health of Children With Cerebral Palsy[NCT04392063]	40 participants (Actual)	Interventional	2016-06-30	Completed
Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea[NCT01196117]	18 participants (Actual)	Interventional	2004-11-15	Completed
Benefice Assessment of Repetitive Transcranial Magnetic Stimulation Used as an Additional Procedure to Rehabilitation Exercises in Patients Suffering From Fibromyalgia[NCT01308801]	42 participants (Actual)	Interventional	2011-04-30	Completed
Evaluation of Spa Therapy in the Treatment of Fibromyalgia : a Randomized, Controlled, Open Multicenter Study[NCT02265029]	220 participants (Actual)	Interventional	2014-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Epworth Sleepiness Score (ESS) is a scale to assess sleepiness during waking hours. The scale ranges from 0-24 with higher scores indicative of greater sleepiness. (NCT01196117)
Timeframe: Difference between Baseline(Day 0) and Average of Day 1,7,14.

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~ 7am, Day 7

Intervention	units on a scale (Median)
14 Days of Placebo Therapy, Then CPAP	10.7
14 Days of CPAP Therapy	8.9

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 7, 7am

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 0

Intervention	nmol/l (Mean)
CPAP>= 3 Hours Per Night	9.9
CPAP<3 Hours Per Night	13.3

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 0, 11pm

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 1

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	3.2
CPAP<3 Hours Per Night	1.2

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 1, 11pm

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 14

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	2.2
CPAP<3 Hours Per Night	1.8

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 14, 11pm

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 7

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	1.9
CPAP<3 Hours Per Night	2.2

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 7, 11pm

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~7am, Day 0

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	3.0
CPAP<3 Hours Per Night	2.5

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 0, 7am

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~7am, Day 1

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	12.5
CPAP<3 Hours Per Night	12.1

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 1, 7am

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~7am, Day 14

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	7.4
CPAP<3 Hours Per Night	13.6

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 14, 7am

Article	Year
[Sleep disorders in patients with a neurocognitive disorder]. L'Encephale, 2022, Volume: 48, Issue:3 Topics: Alzheimer Disease; Chronobiology Disorders; Humans; Melatonin; REM Sleep Behavior Disorder; Restless	2022
Sleep Disorders. The American journal of medicine, 2019, Volume: 132, Issue:3 Topics: Central Nervous System Depressants; Central Nervous System Stimulants; Chronobiology Disorders; Cogn	2019
[Physiological and pathophysiological role of the circadian clock system]. Orvosi hetilap, 2012, Sep-02, Volume: 153, Issue:35 Topics: Aging; ARNTL Transcription Factors; Blood Coagulation Disorders; Cardiovascular Diseases; Circadian	2012
Sleep disorders in Alzheimer's disease and other dementias. Clinical cornerstone, 2004, Volume: 6 Suppl 1A Topics: Accidental Falls; Alzheimer Disease; Antipsychotic Agents; Body Temperature Regulation; Chronobiolog	2004
Menopause related sleep disorders. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2005, Jul-15, Volume: 1, Issue:3 Topics: Depression; Estrogen Replacement Therapy; Estrogens; Female; Fibromyalgia; Humans; Hydrocortisone; M	2005
Sex, steroids, and sleep: a review. Sleep, 1999, Aug-01, Volume: 22, Issue:5 Topics: Animals; Depressive Disorder; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Hyp	1999
[Sleep in fibromyalgia: review of clinical and polysomnographic data]. Neurophysiologie clinique = Clinical neurophysiology, 2001, Volume: 31, Issue:1 Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Arousal; Circadian Rhythm; Depression; Female; Fib	2001
[Sleep in fibromyalgia: review of clinical and polysomnographic data]. Neurophysiologie clinique = Clinical neurophysiology, 2001, Volume: 31, Issue:1 Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Arousal; Circadian Rhythm; Depression; Female; Fib	2001
[Sleep in fibromyalgia: review of clinical and polysomnographic data]. Neurophysiologie clinique = Clinical neurophysiology, 2001, Volume: 31, Issue:1 Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Arousal; Circadian Rhythm; Depression; Female; Fib	2001
[Sleep in fibromyalgia: review of clinical and polysomnographic data]. Neurophysiologie clinique = Clinical neurophysiology, 2001, Volume: 31, Issue:1 Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Arousal; Circadian Rhythm; Depression; Female; Fib	2001

Article	Year
Melatonin and sleep-related problems in children with intractable epilepsy. Pediatric neurology, 2010, Volume: 42, Issue:4 Topics: Adolescent; Bruxism; Child; Child, Preschool; Epilepsy; Female; Humans; Hypnotics and Sedatives; Mal	2010
Melatonin - a somniferous option which does not aggravate sleep-disordered breathing in cardiac risk patients: a Holter ECG based study. Kardiologia polska, 2012, Volume: 70, Issue:1 Topics: Aged; Aged, 80 and over; Central Nervous System Depressants; Circadian Rhythm; Coronary Artery Disea	2012

Article	Year
Parent survey of sleep problems among children with CHARGE syndrome. Research in developmental disabilities, 2020, Volume: 101 Topics: Adolescent; Anxiety; Central Nervous System Depressants; CHARGE Syndrome; Child; Child, Preschool; C	2020
Young children with Down syndrome show normal development of circadian rhythms, but poor sleep efficiency: a cross-sectional study across the first 60 months of life. Sleep medicine, 2017, Volume: 33 Topics: Actigraphy; Child; Child, Preschool; Circadian Rhythm; Cross-Sectional Studies; Down Syndrome; Femal	2017
NREM parasomnias: a treatment approach based upon a retrospective case series of 512 patients. Sleep medicine, 2019, Volume: 53 Topics: Adult; Antioxidants; Benzodiazepines; Cognitive Behavioral Therapy; Female; Humans; Male; Melatonin;	2019
Antioxidants inhibit the inflammatory and apoptotic processes in an intermittent hypoxia model of sleep apnea. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2015, Volume: 64, Issue:1 Topics: Acetylcysteine; Animals; Antioxidants; Apoptosis; Caspases; Disease Models, Animal; Hypoxia; Hypoxia	2015
[Sleep Disturbances in the Elderly]. Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:16 Topics: Aged; Aged, 80 and over; Aging; Cataract; Circadian Rhythm; Humans; Melatonin; Sleep Apnea Syndromes	2016
[Comment to article Pacjent z OSA - o czym warto pamiętać?]. Kardiologia polska, 2012, Volume: 70, Issue:1 Topics: Central Nervous System Depressants; Coronary Artery Disease; Female; Humans; Male; Melatonin; Sleep	2012
Sleep disorders. The Medical clinics of North America, 2003, Volume: 87, Issue:4 Topics: Adult; Aged; Antioxidants; Cheyne-Stokes Respiration; Chronobiology Disorders; Chronotherapy; Disord	2003
REM sleep behaviour disorder treated with melatonin in a patient with Alzheimer's disease. Clinical neurology and neurosurgery, 2008, Volume: 110, Issue:5 Topics: Aged; Alzheimer Disease; Diagnosis, Differential; Hormones; Humans; Male; Melatonin; Polysomnography	2008
Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. American journal of respiratory and critical care medicine, 1996, Volume: 153, Issue:3 Topics: Adult; Aged; Cells, Cultured; Circadian Rhythm; Cytokines; Female; Hormones; Humans; Hydrocortisone;	1996
Melatonin secretion and excretion in patients with obstructive sleep apnea syndrome. Sleep, 1997, Volume: 20, Issue:11 Topics: Adult; Aged; Body Mass Index; Circadian Rhythm; Humans; Male; Melatonin; Middle Aged; Norepinephrine	1997
Afternoon serum-melatonin in sleep disordered breathing. Journal of internal medicine, 1998, Volume: 244, Issue:2 Topics: Adult; Bedding and Linens; Case-Control Studies; Circadian Rhythm; Female; Humans; Male; Melatonin;	1998

melatonin and Sleep Apnea Syndromes